Delivery and expression of the herpes simplex virus thymidine kinase (HSVtk) gene in combination with the prodrug ganciclovir is currently being evaluated for the treatment of many types of cancer. After initial phosphorylation by HSVtk, cellular kinases generate the toxic triphosphate form of ganciclovir (GCV). To further define the role of GCV metabolism in cells expressing HSVtk, two human tumor cell lines, UMSCC29 and T98G, were transduced with HSVtk and screened for insertion of one or two copies of the viral transgene by Southern blot analysis. Both the relative capacities for incorporating labeled GCV and the levels of GCV metabolites were determined for each of the parental cell lines and their derivatives containing either one or two copies of the HSVtk gene. The efficiency of GCV killing and the magnitude of the bystander effect were compared for the single-and double-copy HSVtk cell lines. Consistently, cells that expressed two copies of HSVtk metabolized GCV more efficiently, were more sensitive to GCV, and demonstrated improved bystander killing relative to single-copy HSVtk cells. The implications of these results for future and current therapies employing HSVtk and GCV are discussed. Cancer Gene Therapy (2000) 7, 240 -246
O ne approach for developing new therapies for cancer has been the use of a gene that, when introduced into proliferating cells, produces a product that renders cells sensitive to an otherwise nontoxic drug. One of the most prevalent examples of this type of therapy is the use of the herpes simplex virus thymidine kinase (HSVTK) in combination with ganciclovir (GCV). 1, 2 Commonly used as an anti-herpetic agent, and more recently in an anti-cancer gene therapy strategy, HSVTK phosphorylates GCV to its monophosphate, GCVMP. Cellular kinases further anabolize GCVMP to the cytotoxic triphosphate form, GCVTP, which acts as an inhibitor of DNA polymerase 3, 4 and is incorporated into DNA. 5, 6 In addition to being cytotoxic to cells that express HSVtk, GCV is also capable of killing adjacent cells that lack HSVtk. This phenomenon of cooperative cell killing has been termed the "bystander effect." 7, 8 Thus, in principle, only a fraction of the cells in a tumor need to express HSVtk to obtain a large antitumoral effect after GCV administration. This approach has a significant advantage over strategies in which introduction of a therapeutic gene requires transduction of all of the cells in a tumor to effect significant tumor reduction.
The primary mechanism of the bystander effect in vitro has been attributed to connexin 43-mediated gap junction intercellular communication, involving the passage of cytotoxic phosphorylated GCV derivatives between cells. 9 -14 However, other factors, such as GCV-induced apoptosis of cells that express HSVtk, may also play a role. 8, 15 It has been reported that gap junction-mediated transfer of GCV metabolites from cells that express HSVtk cells to bystander cells begins within 2 hours of drug addition, preceding any cellular apoptotic events. 13 Experiments in vivo have suggested an additional advantage to HSVtk suicide gene therapy, involving an inflammatory immune response directed against the tumor. 16 -19 Cell death that is mediated by HSVtk expression and GCV administration results in an antitumoral response not only to cells that express HSVtk but also to distant tumor cells that are HSVtk negative. This phenomenon has been termed the "distant" bystander effect. 16,20 -22 If metabolic cooperation plays a significant role in the bystander effect, it should be possible to increase the efficiency of cooperative killing of cells that lack HSVTK by cells that express HSVtk by increasing their level of HSVTK activity and thereby increasing their capacity to metabolize GCV. This can be accomplished by selecting for mutant TK enzymes that have increased efficiency for selectively phosphorylating GCV. 23, 24 Alternatively, HSVTK activity can be elevated by transducing cells with multiple copies of the viral gene, or by driving expression of the viral gene with a powerful promoter. Although each method should result in increased expression of HSVtk and therefore produce more GCVMP, enhanced cell killing and a bystander effect would only result if there was a corresponding increase in GCVTP levels. To address these questions, we have transduced two human tumor cell lines with HSVtk and identified cells by Southern blotting that have either one or two copies of the transgene. The relative capacities to metabolize and incorporate GCV as well as the levels and distribution of GCVMP, GCV disphosphate (GCVDP), and GCVTP were determined for each cell line. Also, the effect of HSVtk copy number on the efficacy of GCV-mediated killing and cooperative bystander sensitivities was determined.
MATERIALS AND METHODS

Cell culture and maintenance
The cell lines used in this study included UMSCC29, derived from a human oral squamous cell carcinoma (kindly provided by Dr. Thomas Carey, University of Michigan, Ann Arbor, Mich), and T98G, an established human glioblastoma cell line. 25 Cells were maintained in Dulbecco's modified Eagle's medium containing 4.5 g/L glucose and 10% fetal bovine sera at 37°C in a humidified atmosphere.
Gene transfer
The T98G cells were transfected with G1TkSvNa7 plasmid DNA 9 by calcium phosphate precipitation. G418-resistant clones were selected for 14 days in 1 mg/mL G418, and 20 independent colonies were picked for further analysis. DNAs were isolated, digested with XbaI (New England Biolabs, Beverly, Mass), fractionated by agarose gel electrophoresis, 26 and blotted onto Gene Screen Plus (New England Nuclear, Boston, Mass). The blotted DNAs were hybridized with 32 Pradiolabeled HSVtk DNA labeled by random priming (New England Nuclear) to a specific activity of ϳ10 9 cpm/mL. As a control for loading, the same blots were hybridized with a cDNA encoding adenine phosphoribosyltransferase (APRT) 27 labeled to the same specific activity. The XbaI digestion of G1TkSvNa7 DNA produces a 4.2-kb fragment whose intensity with respect to APRT DNA was quantitated with a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif).
The UMSCC29 cells were first infected with retrovirus from supernatant producer cells derived from PA317 packaging cells 28 that had been transfected with G1TkSvNa7 DNA. Infected cells were selected by drug resistance after culture for 14 days in 1 mg/mL G418. Individual colonies were picked, and their DNAs were digested with XbaI, fractionated, and digested by electrophoresis. The DNAs were blotted as described previously and hybridized with an HSVtk probe to ensure a single copy 4.2-kb fragment characteristic of G1TkSvNa7 DNA. One such subclone was expanded and infected with retrovirus from producer cells PA317/pBabePuro HSVtk, 9 and colonies resistant to 2 g/mL puromycin were selected. DNA was isolated, digested with XbaI, and subjected to Southern blotting with an HSVtk probe to ensure the presence of a second band at 2.5 kb, characteristic of pBabePuro-HSVtk.
Measurement of HSVTK protein level
Each cell line was removed with trypsin, and cell numbers were counted with a hemocytometer. A total of 0.1 mL of a protein solubilizing solution (1 M urea, 5 mM dithiothreitol, 25 mM tris(hydroxymethyl)aminomethane (Tris) (pH 8.0), 1% sodium dodecyl sulfate, and bromophenol blue) was added to a 1.3 ϫ 10 6 T98G cell series or to 0.9 ϫ 10 6 UMSCC cells pelleted in a 1.5-mL microfuge tube. The samples were boiled for 5 minutes and immediately loaded on a 12% sodium dodecyl sulfate-polyacrylamide gel. Protein was transferred to a nitrocellulose membrane, blocked in Tris-buffered saline/5% milk, and incubated with primary HSV-1 TK rabbit polyclonal antibody (a gift from Dr. Margaret Black, Washington State University, Seattle, Wash). A secondary horseradish peroxidase antibody and enhanced chemiluminescent reagents (Amersham, Arlington Heights, Ill) were used to visualize the HSV-1 TK protein bands on film.
Cellular assay for relative HSVTK activities and [ 3 H]GCV incorporation
Parental cells (UMSCC29 and T98G) as well as cells with a single copy of HSVtk (UMSCC29tkS and T98GtkS) and cells with two copies of HSVtk (UMSCC29tkD and T98GtkD) were plated in 10-cm dishes at a density of 10 3 cells/cm 2 . The cells were exposed to [ 3 H]GCV (Moravek Biochemicals, Brea, Calif) at 5 Ci/mL, 20 Ci/mmol, for 24 hours. At that time, the medium was aspirated; cells were washed three times with Hanks' balanced salt solution, suspended by trypsinization, and pelleted by centrifugation. The supernatant was removed, 1.0 mL of cold trichloroacetic acid was added to the pellet, and the resulting macromolecular precipitate was mixed and allowed to stand for 20 minutes in ice. After pelleting by centrifugation, a 0.1-mL aliquot of the supernatant was spotted on a filter, dried, and counted as a relative measure of acid-soluble, unincorporated [ 3 H]GCV. To measure relative [ 3 H]GCV incorporation into nucleic acid, the precipitate was washed three times with cold 5% trichloroacetic acid, once with a 1:4 mixture of ethanol-ether, and once with ether. The dried precipitates were redissolved in 1.0 mL of 0.3N KOH, and 1.0 mL was spotted on a filter and counted.
Determination of GCV metabolites
The method for the identification of GCV metabolites has been described previously. 29 For evaluation of the GCV metabolites, cells were treated for 24 hours with 2 mCi [ 3 H]GCV (10 mM). After removal of media and rinsing twice with phosphate-buffered saline, cells were removed from the plate by trypsinization, pelleted, and resuspended in 0.2 mL of ice-cold 70% methanol. After 15 minutes on ice and frequent vortexing, the remaining cell debris was pelleted. The soluble metabolites were dried under nitrogen, resuspended in 10 L of water, and applied to a polyethylene imine (PEI)-cellulose thin layer chromatography plate. This plate was developed in 0.8 M LiCl, dried, and subdivided into individual 1-cm lanes. For each lane, 1-cm portions were sequentially excised, and radioactivity was determined by scintillation counting. In a separate lane, GCV, guanosine monophosphate (GMP), guanosine diphosphate, and guanosine triphosphate standards were run for identification of the radiolabeled peaks.
RESULTS
Production and characterization of cell lines with variable HSVtk copy number
Cell lines containing single and double copies of HSVtk were obtained either by successive infection with retroviral vectors conferring either resistance to G418 or puromycin or by calcium phosphate-mediated transfection followed by Southern blot analysis. Figure 1 shows Southern blots depicting clones of UMSCC29 cells and T98G cells containing 0, 1, and 2 copies of HSVtk. In the case of UMSCC29 subclones, which were produced by retroviral infection, UMSCC29tkS (single copy) had a single 4.2-kb fragment, whereas UMSCC29tkD (two copies) had an additional band consistent with two independent integration sites. The T98G subclones T98GtkS (single copy) and T98GtkD (two copies) were generated by calcium phosphate transfection. The T98GtkS cell line produced a single 4.2-kb band when probed with an HSVtk probe, as did DNA from T98GtkD, but with twice the density, suggestive of two copies integrated at the same site. Consistent with increased gene copy number, UMSCC29tkD and T98GtkD both had levels of HSVTK protein that were distinctly higher than their single copy counterparts (Fig  2) . There was no detectable signal for HSVTK protein in the nontransduced parental cells.
To test whether increased HSVtk copy number and increased level of HSVTK protein translates into increased capacity to take up GCV and incorporate it into nucleic acids, cells were labeled with [ 3 H]GCV for 24 hours and radioactivity in nucleic acids and total intracellular radioactivity were assessed. GCV is a poor substrate for cellular nucleoside kinases and, as expected, the parental cells, T98G and UMSCC29, incorporated little labeled GCV (Fig 3) (Fig 3) .
Distribution of phosphorylated GCV products
Although cells with two HSVtk copies incorporate more [ 3 H]GCV over a 24-hour period than cells with one HSVtk copy, augmentation of cytotoxic activity and increased bystander effect could be limited by the capacity of cellular kinases to convert GCVMP to GCVTP. To examine the efficiency of GCVTP production, the distribution of phosphorylated GCV products was determined by thin layer chromatography after exposure of the UMSCC29 and T98G parental cells and their HSVtk-transduced derivatives to [ 3 H]GCV. 29 Results are presented in Table 1 . As expected, parental cells revealed negligible GCV metabolism, whereas the T98Gtk cells showed significantly higher GCV metabolite profiles compared with the UMSCC29tk cells. Comparison of cells with one copy versus two copies of HSVtk showed that in both cell types, cells with two copies of HSVtk led to an ϳ4-fold or greater increase in GCV metabolites than cells with a single HSVtk copy. The predominant phosphorylated form of GCV was GCVTP in the T98Gtk cells, whereas GCVMP was the predominant species in the UMSCC29tk cells.
Increased cytotoxicity and bystander effect with increased HSVtk copy number
The increased levels of GCVTP should render cells more sensitive to GCV and should produce an exaggerated bystander effect. To assess the relative sensitivity of cells with one or two HSVtk copies, UMSCC29tkS and UMSCC29tkD cells as well as T98GtkS and T98GtkD cells were placed individually into culture medium containing 20 M of GCV. In both cases, parental cells were unaffected by GCV treatment and continued to grow without impediment. Figure 4A shows that UMSCC29 cells with two HSVtk copies were more sensitive to GCV than cells with a single copy (P Ͻ .05). The same trend was seen in the T98G derivatives, but the difference in cell killing between the two lines was not statistically different (Fig 4B) . This may be due to the very high GCVTP values observed in the T98GtkS cells (Table 1) . Differences in cooperative killing between singly and doubly transfected cells were assessed by coculture with naive cells lacking HSVtk and by concomitant exposure to GCV. The T98G cell derivatives consistently showed a more efficient bystander effect than the UMSCC29 cell derivatives (Fig 5) , again reflective of their higher GCVTP levels. Similarly, cooperative killing was more efficient when the cells housed two HSVtk copies compared with cells with a single copy (Fig 5, A and B) .
DISCUSSION
This report clearly demonstrates a dosage effect for the HSVtk bystander effect. Expression of two HSVtk genes in bystander-competent tumor cell lines increases the rate of tumor cell killing and GCV metabolite transfer relative to corresponding single-copy HSVtk cell lines. For clinical in vivo applications, this enhanced metabolism could increase the extent and rate of tumor cell killing and increase the available intracellular concentrations of phosphorylated GCV metabolites for gap junction-mediated transfer to adjacent cells. Either or both effects might potentiate an antitumoral immune response and an overall increase in the in vivo bystander effect. Transfer of GCV metabolites in tumor cell lines that are bystander competent can occur within 2 hours of drug administration, 13 and DNA synthesis appears to be inhibited after only 6 hours of GCV treatment. 30 Even in tumor cells that are resistant to bystander transfer, efficient and rapid transfer of HSVtk-expressing cells would be desirable. Clearly, the higher the level of GCV metabolism by HSVtk, the greater the benefit for cancer gene therapies.
Our results with the two different tumor cell lines, UMSCC29 and T98G, and their derivatives also highlight an often overlooked aspect of HSVtk/GCV therapy, namely the roles of the intermediate kinases involved in converting GCVMP to GCVTP and the subsequent inhibition of DNA polymerase. After phosphorylation by HSVTK, GCVMP is an effective substrate for GMP kinase to produce GCVDP 31 and for subsequent activity by an isoform of nucleoside 5Ј-diphosphate-kinase that generates GCVTP. A K i of 10 M has been determined previously for GCVTP inhibition of DNA polymerase ␣ purified from HeLa cells. 3 Although this value is high relative to that determined for acyclovir triphosphate (K i ϭ 0.44 M 3 ), the cellular half-life and retention of GCVTP 3, 5, 6, 31 forms the basis for the effectiveness of GCV for cancer gene therapy. In HSVtk-transduced T lymphocytes, for example, GCV treatment for 1 day results in the same level of cell death after 5 days as cells treated continually for 3-5 days. ) were labeled for 24 hours with 2 Ci of [ 3 H]GCV and 10 M of GCV. Metabolites were extracted in 70% methanol and separated on PEI-cellulose thin layer chromatography plates as described previously. 29 The values are representative of three independent determinations. Similar results have been reported for HSVtk-expressing colon tumor and glioma cell lines. 5, 6 Because of the retention and the stability of GCVTP, even low expression of HSVtk will eventually result in the accumulation of sufficient GCVTP levels to cause cell death after a threshold level for saturation of DNA polymerase is attained.
Among the cell lines examined, the UMSCC29 cells had a unique GCV metabolite pattern, in that the predominant GCV form was GCVMP. This would suggest that GMP kinase and nucleoside 5Ј-diphosphate-kinase levels may be limiting in this cell line. Nevertheless, sufficient GCVTP is generated to result in half-maximal cell death after 3-4 days of GCV treatment (Fig 4A) . The predominant form of GCV in the T98G cells was GCVTP. This result is consistent with other studies that have examined GCV metabolites in HSVtk-transduced cell lines: GCVTP was the predominant isolated metabolite. 5, 6, 14, 29, 30 The host cellular kinases that convert GCVMP to GCVTP are likely to be variable in many cell types and tissues, as demonstrated by the results obtained with these two cell lines. Because HSVtk/GCV therapy is targeted to replicating tumor cells that must have these kinases for growth, the levels of these kinase activities are unlikely to be as important as the level of the HSVtk activity. UMSCC29 cells grow more slowly than T98G cells, and this difference may be reflected in the GCV metabolism data that we report for these cell lines. Despite the much higher levels of GCV metabolism and the increased rate of cell killing in the double-copy T98GtkD cell line compared with the UMSCC29tkD cells, ϳ77% of cells from both lines were dead after 4 days of GCV treatment (Fig 4, A and B) . Interestingly, the same percentage of rapidly metabolizing single-copy T98GtkS cells were dead as cells with two HSVtk copies by day 4, whereas only 50% of the single-copy UMSCC29 cells were dead at this same timepoint. These results suggest that there is a threshold level of GCVTP that ultimately results in cell death, and that this threshold level is directly related to the amount of HSVtk expressed. Thus, slowly growing cells such as UMSCC29 cells with one HSVtk copy display suboptimal GCV metabolism, whereas two HSVtk copies confer GCV metabolism abilities similar to those of fast-growing and higher GCV-metabolizing cell lines such as T98GtkS. Similar conclusions were reached after evaluating GCV effects in a series of rat 9L glioma cells characterized by different HSVtk mRNA/expression levels 32 and in colon tumor cell lines. 5 A GCV threshold was reached beyond which the rate of cell killing did not change. This conclusion is also supported by previous studies employing HSVtk mutants with increased GCV phosphorylation capabilities. 24 It was demonstrated that these mutants required less GCV doses to efficiently kill cells (i.e., the minimal GCVTP inhibitory threshold was more efficiently reached). 24 In aggregate, these results indicate that any approach that improves GCV phosphorylation will result in increased efficacy of HSVtk/GCV therapy.
